Products and methods for treating diseases or disorders associated with DUX4 overexpression
NZ837788AUndetermined Publication Date: 2025-10-09ARMATUS BIO INC +1
-1 Cites 0 Cited by
Patent Information
- Application Number
- NZ837788
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-03
- Filing Date
- 2025-04-03
- Publication Date
- 2025-10-09
AI Technical Summary
Technical Problem
There is a need for effective treatments to inhibit DUX4 expression and treat or prevent muscular dystrophies and cancers associated with DUX4 overexpression, as current therapies are lacking.
Method used
The use of DUX4-targeting microRNAs and recombinant adeno-associated virus (AAV) vectors to deliver these microRNAs to cells, specifically using modified AAV9 or AAV-SLB101 capsids, to inhibit DUX4 expression and treat or prevent associated diseases.
Benefits of technology
The approach effectively inhibits DUX4 expression, showing therapeutic benefits in treating or preventing muscular dystrophies such as facioscapulohumeral muscular dystrophy (FSHD) and cancers by reducing disease progression and improving patient quality of life.
✦ Generated by Eureka AI based on patent content.
Smart Images

Figure 00000065_0000 
Figure 00000066_0000 
Figure 00000066_0001
Abstract
Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing a muscular dystrophy or a cancer including, but not limited to, facioscapulohumeral muscular dystrophy (FSHD) or a cancer associated with DUX4 expression or overexpression. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of double homeobox 4 (DUX4). Even more particularly, the disclosure provides microRNA (miRNA) (and vectors and compositions comprising the miRNA encoding polynucleotides) for inhibiting or downregulating the expression of DUX4 and methods of using said miRNA to inhibit or downregulate DUX4 expression in cells and / or in cells of a subject having a muscular dystrophy or a cancer associated with DUX4 expression or overexpression including, but not limited to, FSHD or a cancer associated with DUX4 expression or overexpression.
Need to check novelty before this filing date? Find Prior Art
